HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network
JNCI Cancer Spectrum · 07.07.2026 · 10 (4)
DOI: 10.1093/jncics/pkag076 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 13.08.2026. Verfasst von Shih-Ping Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of internal medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Hodgkin Disease, HIV Infections, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taichung Veterans General Hospital.
Abstract (Originalsprache)
Background
Despite effective antiretroviral therapy, people living with human immunodeficiency virus (HIV) (PLWH) remain at a higher risk of developing Hodgkin lymphoma (HL). Further, survival disparities persist despite similar treatment recommendations.
Methods
Herein, we present a global retrospective cohort study including data of adults (≥18 years) diagnosed with HL between 2015 and 2025 from the TriNetX database to evaluate the survival outcomes of Hodgkin lymphoma in HIV-infected vs non-HIV-infected patients and analyze the associated risk factors. Patients were stratified according to HIV status and matched 1:1 for age, sex, race, and comorbidities. Overall survival (OS) was analyzed using Kaplan-Meier and Cox proportional hazards models.
Results
A total of 927 matched HIV-infected and non-HIV-infected patients were included. Overall, HIV-positive status was associated with significantly inferior OS (HR 1.42; 95% CI 1.10-1.84; P = .033). Among PLWH, cerebrovascular disease, hepatitis C virus infection, and chronic kidney disease independently predicted increased mortality. In a matched subgroup of patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy (n = 154 per group), OS did not differ significantly between the HIV-positive and HIV-negative groups (HR 1.37; 95% CI 0.73-2.56; P = .247).
Conclusion
In conclusion, HIV-infected patients with HL experienced worse OS compared with non-HIV-infected individuals, but the outcomes were comparable when treated with ABVD chemotherapy, highlighting the importance of optimal treatment delivery and comorbidity management in PLWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of internal medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
- Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
ORCID-Profile: Jian-Ri Li, Cheng-Wei Chou
Förderung
- Taichung Veterans General Hospital
Zitieren
APA
Lin, S. P., Yen, T. H., Li, J. R., & Chou, C. W. (2026). HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network. JNCI Cancer Spectrum, 10(4). https://doi.org/10.1093/jncics/pkag076
Vancouver
Lin SP, Yen TH, Li JR, Chou CW. HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network. JNCI Cancer Spectrum. 2026;10(4). doi:10.1093/jncics/pkag076
BibTeX
@article{Lin2026,
author = {Lin, Shih-Ping and Yen, Tsung-Han and Li, Jian-Ri and Chou, Cheng-Wei},
title = {HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {4},
doi = {10.1093/jncics/pkag076}
}
EUVIMED